Haihe Biopharma Co., Ltd.
Haihe Biopharma Co., Ltd.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) | PIK3CA-Related Overgrowth Spectrum (PROS); PIK3CA-related Vascular Malformations (PRVM) | Recruiting | Phase 1 / Phase 2 | 2026-06-29 | NCT06975618 | |
| Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-30 | NCT06909877 | |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2026-01-30 | NCT05043922 | |
| Evaluate the Safety and Clinical Activity of HH2853 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, T-cell non-Hodgkin lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-01-30 | NCT04390737 | |
| Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | C-Met Exon 14 Mutation | Recruiting | Phase 1 / Phase 2 | 2022-08-01 | NCT04270591 |